Leo Pharma sells development program, becomes shareholder of Swedish biotech buyer

International attention continues to be fixed on Leo Pharma, which saw its CEO Catherine Mazzacco step down with immediate effect last week.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Headhunter calls outgoing Leo Pharma CEO a "flop"
For subscribers
CSL eyeing acquisition candidate in Vifor Pharma
For subscribers